Abstract 30P
Background
Oral squamous cell carcinoma (OSCC) represents one of the six most common cancers in the world. The identification of new prognostic markers could help clinicians explore the biological characteristics of OSCC and develop more personalized treatment plans for patients based on their risk factors. The discovery and study of new prognostic markers of OSCC may help improve treatment outcomes through more accurate and effective treatment strategies, ultimately leading to improved survival and quality of life in patients with OSCC. The aim of this study was to identify the prognostic value of CDKN2A and miRNAs, involved in its regulation as markers of OSCC.
Methods
In the present study we have results of the examination and treatment of 70 patients with stage II–IV OSCC. miR-10b and -155 and mRNA of CDKN2A in tumor samples of patients with OSCC was analyzed by real-time reverse transcription polymerase chain reaction. Detection of p16INK4a was performed by simultaneous immunohistochemical assessment in tumor cells.
Results
We found a strong correlation of studied miRNAs expression with lymph node metastasis (r=0.56 for miR-10b and 0.59 for miR-155). Also, there is no differences in miR-10b and -155 between p16INK4a+ and p16INK4a- samples. p16INK4a status does not affect the association of both miRNAs with lymph node metastases.
Conclusions
The results indicate the relation between miR-10b and -155 and the presence of lymph node metastases of patients with OSCC and thus they can be used as prognostic markers of the disease.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
158P - Enhancing the communication of genomic results: Understanding patient and clinician perspectives
Presenter: Eleanor Johnston
Session: Cocktail & Poster Display session
Resources:
Abstract
159P - Precision medicine-based platform to guide the treatment of EML4-ALK fusion lung cancers and other NSCLC
Presenter: Nathan Merrill
Session: Cocktail & Poster Display session
Resources:
Abstract
160P - CICLADES-CE study: Genomic signatures detected in DNA from FFPE samples of patients with advanced or metastatic breast cancers treated with anti-aromatase and CDK4/6 inhibitors
Presenter: Margaux BETZ
Session: Cocktail & Poster Display session
Resources:
Abstract
161P - PDL1 expression and its relation to EML4-ALK gene variants in metastatic lung adenocarcinoma: A single-center real-world experience
Presenter: Santhosh Meedimale
Session: Cocktail & Poster Display session
Resources:
Abstract
163P - Impact of genomic sequencing data on treatment decisions in advanced breast cancer (ABC)
Presenter: Sviatoslav Chekhun
Session: Cocktail & Poster Display session
Resources:
Abstract
164P - Clinical utility of comprehensive molecular profiling tests for advanced gastrointestinal tumors
Presenter: Alexandra Lebedeva
Session: Cocktail & Poster Display session
Resources:
Abstract
165P - Evaluation of the mutational profile in patients with metastatic non-small cell lung carcinoma diagnosed in a tertiary hospital which was performed by NGS method
Presenter: Kankan Deka
Session: Cocktail & Poster Display session
Resources:
Abstract
166P - Targeted next-generation sequencing as reliable detection of genetic profile for cancer treatment to guide oncologists in Pakistan
Presenter: Zeeshan Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
167P - Molecular analysis of gastrointestinal stromal tumor (GIST): The experience of Regina Elena National Cancer Institute
Presenter: Andrea Torchia
Session: Cocktail & Poster Display session
Resources:
Abstract
168P - Usefulness of liquid biopsy in the management of patients with advanced or metastatic pancreatic cancer
Presenter: Jorge Iranzo Barreira
Session: Cocktail & Poster Display session
Resources:
Abstract